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Introduction: Training in correct inhaler use, ideally in person or by video demonstration,
can minimize errors but is rarely provided in clinics. This open-label, low-intervention study
evaluated critical error rates with dry-powder inhalers (DPIs), before and after training, in
patients with chronic obstructive pulmonary disease.
Methods: Patients prescribed an inhaled corticosteroid (ICS)/long-acting β2-agonist
(LABA) (ELLIPTA, Turbuhaler, or DISKUS), long-acting muscarinic antagonist (LAMA)/
LABA (ELLIPTA or Breezhaler), or LAMA-only DPI (ELLIPTA, HandiHaler, or
Breezhaler) were enrolled. Critical errors were assessed before training (Visit 1 [V1];
primary endpoint) and 6 weeks thereafter (Visit 2 [V2]; secondary endpoint). Logistic
regression models were used to calculate odds ratios (ORs) for between-group comparisons.
Results: The intent-to-treat population comprised 450 patients. At V1, fewer patients made ≥1
critical error with ELLIPTA (10%) versus other ICS/LABA DPIs (Turbuhaler: 40%, OR 4.66,
P=0.005; DISKUS: 26%, OR 2.48, P=0.114) and other LAMA or LAMA/LABA DPIs
(HandiHaler: 34%, OR 3.50, P=0.026; Breezhaler: 33%, OR 3.94, P=0.012). Critical error
rates with the primary ICS/LABA DPI were not significantly different between ELLIPTA
ICS/LABA (10%) and ICS/LABA plus LAMA groups (12–25%). Critical errors with the
primary ICS/LABA DPI occurred less frequently with ELLIPTA ICS/LABA with or without
LAMA (11%) versus Turbuhaler ICS/LABAwith or without LAMA (39%, OR 3.99, P<0.001)
and DISKUS ICS/LABAwith or without LAMA (26%, OR 2.18, P=0.069). Simulating single-
inhaler versus multiple-inhaler triple therapy, critical error rates were lower with ELLIPTA
fluticasone furoate/vilanterol (FF/VI; 10%) versus ELLIPTA FF/VI plus LAMA (22%), con-
sidering errors with either DPI (OR 2.50, P=0.108). At V2, critical error rates decreased for all
DPIs/groups, reaching zero only for ELLIPTA. Between-group comparisons were similar to V1.
Conclusion: Fewer patients made critical errors with ELLIPTA versus other ICS/LABA,
and LAMA or LAMA/LABA DPIs. The effect of “verbal” training highlights its importance
for reducing critical errors with common DPIs.
Keywords: inhaler technique, critical errors, ELLIPTA, inhaled corticosteroid, long-acting
β2-agonist, long-acting muscarinic antagonist
Plain Language Summary
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that can have
a significant burden on patients’ everyday lives. In order to treat COPD, patients are prescribed
medications in one or more inhalers; however, many different inhalers are available, each one
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with its own unique mechanism of use, and errors in inhaler tech-
nique are common. So-called “critical” errors can reduce the
amount of medication delivered to an extent which may lead to
poorer disease management and outcomes. One way to reduce
errors in inhaler technique is for healthcare professionals to explain
to patients how to use their inhaler(s) properly and then to monitor
their technique over time. In practice, this often does not occur. In
this study, patients with COPD were receiving COPD treatments
from one or two of five different inhalers (ELLIPTA, HandiHaler,
DISKUS, Turbuhaler, or Breezhaler). Correct use of their inhaler(s)
was assessed at two study visits (Visit 1 and Visit 2). Without
receiving any training at Visit 1, fewer patients made critical errors
with the ELLIPTA inhaler versus the other inhalers tested. At Visit 2
(6 weeks later), after training (if required), the number of patients
making critical errors was much lower for all inhalers and no
patients made critical errors using ELLIPTA alone. Overall, this
study demonstrates the existence of poor inhaler technique and the
importance of training to reduce errors with inhalers used for the
treatment of COPD. Inhaler training may lead to improved treat-
ment outcomes for patients with COPD.
Introduction
Inhaled medications, namely licensed inhaled corticoster-
oid (ICS), long-acting β2-agonist (LABA), and long-acting
muscarinic antagonist (LAMA) combinations, represent
the cornerstone of maintenance therapy for chronic
obstructive pulmonary disease (COPD).1 It is widely
acknowledged, however, that patients frequently make
errors when using their prescribed inhaler(s).2 These
errors, particularly critical errors — those that result in
no, or significantly reduced, medication being inhaled —
are associated with a subsequent negative impact on treat-
ment efficacy and also an increase in the economic burden
associated with treatment.3
Both the type and number of inhalers required to deliver
maintenance regimens can impact the frequency of errors
(critical or otherwise) made by patients. COPD treatments
can be delivered via multiple inhaler types, with different
inhalers often requiring the user to learn different inhalation
techniques.4 The ELLIPTA inhaler, a dry-powder inhaler
(DPI) designed to deliver single agents or their combina-
tions in a single inhalation, demonstrated the fewest critical
errors when compared with other commonly used DPIs and
metered-dose inhalers in clinical studies of COPD.5,6 While
studies of errors in technique have been conducted in both
the real world7 and clinical trial settings5,6 for many differ-
ent inhalers, fewer data exist for more recently available
inhalers such as ELLIPTA. Available data for ELLIPTA
have largely been restricted to the trial setting thus far but
the more widespread use of the ELLIPTA inhaler now
provides an opportunity to study errors in technique in
a routine clinical practice setting.
Optimal inhaler use should result in no (or very few)
errors and successful delivery of medication. Training
from healthcare professionals (HCPs) on correct inhaler
use provides the best outcomes for patient technique in the
clinic, and repetition of training or monitoring of ongoing
inhaler technique reduces errors.1,8 Notably, a lack of
instruction on correct inhaler use from HCPs is signifi-
cantly (P<0.001) associated with risk of critical errors in
patients with COPD or asthma.9 Nevertheless, training on
correct inhaler technique is time-consuming to perform,
while prior evidence shows that a significant proportion of
HCPs have inadequate knowledge of and competency in
correct inhaler use.10,11 In addition, assessment of inhaler
technique over time is only conducted in a small percen-
tage of patients8 and approximately half of patients who
initially use their inhaler correctly do not maintain correct
use over time;8 correct technique may decline within 1
month of receipt of training.12
Given the importance of training for correct inhaler
technique, and the wider use of the ELLIPTA inhaler in
routine clinical practice, we designed the current study to
assess the rate of critical errors with ELLIPTA compared
with a number of other DPIs. Due to the widespread use of
multiple-inhaler triple therapies for COPD in practice,
analyses were conducted for single DPIs and DPI combi-
nations, both before and 6 weeks after refresher training (if
required) on correct technique from an HCP.
Methods
Study Design and Patients
This open-label, low-intervention clinical study was carried
out at 13 centers in the Netherlands (n=9; Catharina
Ziekenhuis, Gelre Ziekenhuis Zutphen, Huisartsenmaatschap
MCN, Huisartsenpraktijk Coenen, PreCare T&R, Q Clinical,
Quality Care Research, Westfries Gasthuis, Ziekenhuisgroep
Twente) and the United Kingdom (n=4; Medinova North
London Clinical Studies Centre, Medinova South London
Clinical Studies Centre, Saint George’s University of
London, William Harvey Heart Clinical Research Centre)
from June 2017 to March 2018. Eligible patients were identi-
fied from community pharmacies and clinical sites (hospitals,
primary care sites, and contract research organizations) based
on the patients’ regular inhaler(s) used to receive COPD
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maintenance medication. Expert training in inhaler technique
was provided to staff at each of the study sites.
Enrolled patients were aged ≥40 years, with a physician’s
diagnosis of COPD, and had received DPI treatment for ≥3
months prior to inclusion: the DPI groups included in this
analysis are summarized in Table 1. Patients could have
received ICS/LABAvia ELLIPTA (fluticasone furoate/vilan-
terol [FF/VI]), Turbuhaler (budesonide/formoterol [BUD/
FOR]), or DISKUS (fluticasone propionate/salmeterol [FP/
SAL]), alone or in combination with a LAMA-only DPI
(ELLIPTA umeclidinium [UMEC] or HandiHaler tiotropium
[TIO]), or LAMA monotherapy via ELLIPTA (UMEC),
HandiHaler (TIO), or Breezhaler (glycopyrronium [GLY]),
or LAMA/LABA dual therapy via ELLIPTA (UMEC/VI) or
Breezhaler (indacaterol/GLY [IND/GLY]). Exclusion criteria
included a current diagnosis of asthma and participation in an
inhaler study that involved training within 6 months of study
entry. All patients provided written, informed consent. The
study was conducted in accordance with the ethical princi-
ples outlined in the Declaration of Helsinki. At all participat-
ing sites, the study was approved by the relevant institutional
review board or ethics committee, as required (EastMidlands
REC – Northampton, UK; Saint Antonius Ziekenhuis, the
Netherlands).
All patients were assessed only on the use of their own
maintenance DPI (no change to a newDPI was investigated).
The study comprised three visits: a screening (enrollment)
visit (V0), a subsequent first assessment visit (Visit 1 [V1];
which could occur on the same day as V0), and a second
assessment visit (Visit 2 [V2]) 6 weeks after V1. Patients’
baseline information (demographics, smoking history,
COPD Assessment Test [CAT] score, medical history, time
on each DPI, time since last trained, and educational infor-
mation) was collected at V0 and errors made with their usual
COPD maintenance DPI(s) were assessed at V1 without any
instruction from their HCP. If the patient made errors at this
stage, they received verbal instruction on correct use of their
DPI(s) from the HCP. If the patient made no errors at this
stage, they did not receive training and were simply informed
of their correct use.
Patients returned for V2 6 weeks (±7 days) after V1; this
time period reflects prior evidence showing a decline in
correct inhaler technique within 1 month of training.12 DPI
errors were assessed and noted, and any changes in health or
prescriptions were captured. All patients were discharged
from the study at V2. Patients were referred to their general
practitioner for further training if they continued to demon-
strate incorrect use of their prescribed DPI at V2.
Endpoints and Assessments
The primary endpoint was the percentage of patients making
≥1 critical error at V1. The key secondary endpoint was the
percentage of patients making ≥1 critical error at V2. The
primary comparisons of interest for this study were the
percentage of patients making ≥1 critical error with each
ICS/LABA DPI (ELLIPTA FF/VI vs other ICS/LABA
DPIs) and with each LAMA or LAMA/LABA DPI
(ELLIPTA UMEC or UMEC/VI vs other LAMA or
LAMA/LABA DPIs). Additional comparisons examined
the effect of adding a secondary LAMA DPI to the primary
ICS/LABA inhaler, from the perspective of critical errors
with the primary DPI and with both DPIs combined.
Comparisons were also conducted to evaluate overall errors
(ie, all errors made, whether classified as critical or non-
critical). Furthermore, to simulate a comparison of single-
inhaler triple therapy (SITT) versus multiple-inhaler triple
therapy (MITT), critical error rates with ELLIPTA FF/VI
alone versus ELLIPTA FF/VI plus LAMAwere investigated.
Patients’ inhaler technique was assessed against
a correct-use checklist for each relevant DPI by HCPs at
each study site. All assessors purposefully received the
same training in correct technique for each of the individual
Table 1 Single and Combination DPI Groups Enrolled in the Study
Single-Inhaler Treatment Groups Dual Inhaler Treatment Groups
Inhaled Medication Class ICS/LABA LAMA or LAMA/LABA ICS/LABA plus LAMA
Primary DPI ELLIPTA Turbuhaler DISKUS ELLIPTA HandiHaler Breezhaler ELLIPTA Turbuhaler DISKUS
FF/VI BUD/FOR FP/SAL UMEC/VI or UMEC TIO IND/GLY or GLY FF/VI BUD/FOR FP/SAL
(n=50) (n=50) (n=50) (n=51) (n=50) (n=49) (n=50) (n=50) (n=50)
Secondary DPI ELLIPTA UMEC or HandiHaler TIO
Abbreviations: BUD, budesonide; DPI, dry-powder inhaler; FF, fluticasone furoate; FOR, formoterol; FP, fluticasone propionate; GLY, glycopyrronium; ICS, inhaled
corticosteroid; IND, indacaterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SAL, salmeterol; TIO, tiotropium; UMEC, umeclidinium; VI,
vilanterol.
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DPIs examined. No universally agreed checklists that define
critical and non-critical errors for specific inhalers currently
exist. Thus, checklists and critical errors for each individual
DPI were developed based on the steps identified in the
patient information leaflet for each inhaler, review of the
available literature, and further review by external experts.5
These checklists were thus as objective as possible and were
used by all study sites. Complete checklists are provided in
the supplementary appendix (Tables S1–S5).
Critical errors, which were the focus of this study, were
defined as those leading to no, or significantly reduced,
medication being inhaled. Errors not meeting this definition
were considered non-critical errors and were recorded for the
purpose of also evaluating overall errors, ie, all errors made,
whether classified as critical or not. The numbers of possible
critical/overall errors for each DPI examined were: 4/9 for
ELLIPTA; 6/12 for Turbuhaler; 5/9 for DISKUS; 7/13 for
HandiHaler; and 7/12 for Breezhaler. Differences between
the DPIs in the number of critical errors potentially reflect
differences in complexity for correct inhaler use.
Statistical Analyses
A planned total of 50 patients in each DPI group was calcu-
lated to provide >94% power to demonstrate a statistically
significant difference between the critical error rates of each
of the paired DPI comparisons, assuming a true critical error
rate of 5% for ELLIPTA and 30% for each of the other DPIs,
based on previous studies.13,14 A two-sided 5% significance
level was assumed to test the difference between critical error
rates for each comparison of interest.
For the pre-specified analyses, the primary and key
secondary endpoints were analyzed using a logistic regres-
sion model, with DPI group as a fixed effect and adjusting
for the covariate of time on current primary DPI. Odds
ratios (ORs), confidence intervals (CIs), and P-values were
calculated for each comparison.
During development of this study, it became apparent
that patients could have been using a particular DPI for
less time than patients who were using other DPIs; for
example, the majority of patients using ELLIPTA and
Breezhaler DPIs had used these for 2 years or fewer,
while most patients using Turbuhaler, DISKUS and
HandiHaler DPIs had been using these for more than 3
years. As a result, there was a clear non-independent
imbalance between time on DPI and treatment cohort
across the different cohorts. Given the non-randomized
design of the study and the potential confounding of the
covariate, inclusion of the parameter of time on DPI
resulted in the possibility that any treatment effect (in
either direction) would be reduced due to this confounding
by DPI type. We therefore also performed post-hoc sensi-
tivity analyses in which the confounded covariate of time
on DPI was removed from the logistic regression models
to minimize the impact of this imbalance. All pre-specified
and post-hoc sensitivity analyses, including those of
safety, were conducted in the intent-to-treat (ITT) popula-
tion, which comprised all patients who were enrolled and
demonstrated use of their primary DPI. Data are presented
for the pre-specified analyses (main text and tables) and
for the post-hoc sensitivity analyses (tables only).
Results
Study Population
Overall, 461 patients were enrolled and 450 comprised the
ITT population. The mean (standard deviation [SD]) age
was 67.2 (9.75) years and 54% were male (Table 2). At
screening, the majority of patients (58%) reported a COPD
duration of between 1 and 10 years. The mean (SD) CAT
score at screening was 16.6 (7.23). Demographic charac-
teristics were largely similar across DPI groups.
Inhaler Errors
Details of the specific errors (critical and non-critical) that
were made by patients for each DPI are presented in the
supplementary appendix (Figure S1). Almost all patients
correctly opened the cover/removed the cap/removed the
capsule of their DPI and formed a firm seal around the
mouthpiece with their lips prior to inhalation. Among
patients making any error (critical or non-critical), the most
common critical error for the ELLIPTA, DISKUS and
Breezhaler DPIs was exhaling directly into the mouthpiece
(prior to medication inhalation) (18%, 37%, and 44% of
patients, respectively). Not holding the inhaler upright (dur-
ing dose preparation) was the most common critical error
with the Turbuhaler DPI (41% of patients), while for the
HandiHaler DPI it was the capsule not rattling, indicating
failure to empty the capsule of medication (24% of patients).
Percentage of Patients Making ≥1 Critical
Error at V1: ICS/LABA and LAMA or
LAMA/LABA Primary DPIs
Patients using the ELLIPTA DPI demonstrated the lowest
critical error rate across the single ICS/LABA DPIs assessed
at V1 (Figure 1). The number of patients making ≥1 critical
error with ELLIPTA FF/VI, Turbuhaler BUD/FOR, and
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DISKUS FP/SAL was 5/50 (10%), 20/50 (40%), and 13/50
(26%), respectively. The OR for making ≥1 critical error with
Turbuhaler BUD/FOR versus ELLIPTA FF/VI was 4.66
(95% CI 1.58–13.69; P=0.005) (Table 3). For the DISKUS
FP/SAL versus ELLIPTA FF/VI comparison, the OR for
making ≥1 critical error was 2.48 (95% CI 0.80–7.63;
P=0.114) (Table 3).
For the LAMAor LAMA/LABADPIs, the ELLIPTADPI
again showed the lowest critical error rate. The number of
patients making ≥1 critical error was 5/51 (10%) with
ELLIPTA UMEC/VI or UMEC, 17/50 (34%) with
HandiHaler TIO, and 16/49 (33%) with Breezhaler IND/
GLY or GLY (Figure 1). This corresponded to an OR for
making ≥1 critical error with HandiHaler TIO versus
ELLIPTA UMEC/VI or UMEC of 3.49 (95% CI 1.16–10.55;
P=0.026), and an OR for making ≥1 critical error with
Breezhaler IND/GLYor GLYversus ELLIPTA UMEC/VI or
UMEC of 3.94 (95% CI 1.35–11.53; P=0.012) (Table 3).
Results of the post-hoc sensitivity analyses excluding
the covariate of time on primary DPI (which was con-
founded with DPI type) mirrored the findings of the pre-
specified analyses, but with slightly higher odds ratios for
almost all comparators (vs ELLIPTA); this pattern was
evident also for the comparisons described below.
Percentage of Patients Making ≥1 Critical
Error at V1: ICS/LABA Plus LAMA Groups
Addition of a LAMA DPI had a minimal effect on critical
error rates with the primary ICS/LABA DPI at V1. The
number of patients making ≥1 critical error was 6/50 (12%)
with ELLIPTA FF/VI, 19/50 (38%) with Turbuhaler BUD/
FOR, and 13/50 (26%) with DISKUS FP/SAL (Figure 1).
≥
Figure 1 Percentage of patients making ≥1 critical error with the primary DPI at V1. LAMA represents ELLIPTA UMEC or HandiHaler TIO.
Abbreviations: BUD, budesonide; DPI, dry-powder inhaler; FF, fluticasone furoate; FOR, formoterol; FP, fluticasone propionate; GLY, glycopyrronium; IND, indacaterol;
LAMA, long-acting muscarinic antagonist; SAL, salmeterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol; V1, Visit 1.
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Table 3 Percentage of Patients Making ≥1 Critical Error with their Prescribed DPI(s) at V1
DPI Group Patients Making ≥1
Critical Error, n (%)
Patients Making No
Critical Errors,
n (%)
OR vs ELLIPTA (95% CI; P-value)
Pre-Specified
Analysesa
Post-Hoc Sensitivity
Analysesb
ICS/LABA
ELLIPTA FF/VI (n=50) 5 (10) 45 (90) ‒ ‒
Turbuhaler BUD/FOR (n=50) 20 (40) 30 (60) 4.66 (1.58–13.69; 0.005) 5.56 (1.93–16.01; 0.001)
DISKUS FP/SAL (n=50) 13 (26) 37 (74) 2.48 (0.80–7.63; 0.114) 2.98 (1.00c–8.88; 0.050)
LAMA/LABA or LAMA only
ELLIPTA UMEC or UMEC/VI (n=51) 5 (10) 46 (90) ‒ ‒
HandiHaler TIO (n=50) 17 (34) 33 (66) 3.49 (1.16–10.55; 0.026) 4.42 (1.52–12.83; 0.006)
Breezhaler IND/GLY or GLY (n=49) 16 (33) 33 (67) 3.94 (1.35–11.53; 0.012) 4.17 (1.42–12.18; 0.009)
ELLIPTA FF/VI alone vs ELLIPTA FF/VI plus LAMA (errors in primary DPI)
ELLIPTA FF/VI (n=50) 5 (10) 45 (90) ‒ ‒
ELLIPTA FF/VI plus LAMA (n=50) 6 (12) 44 (88) 1.22 (0.36–4.15; 0.746) 1.21 (0.36–4.10; 0.761)
ELLIPTA FF/VI alone vs ELLIPTA FF/VI plus LAMA (errors in both DPIs considered)
ELLIPTA FF/VI (n=50) 5 (10) 45 (90) ‒ ‒
ELLIPTA FF/VI plus LAMA (n=50) 11 (22) 39 (78) 2.50 (0.82–7.66; 0.108) 2.41 (0.79–7.33; 0.122)
ELLIPTA FF/VI alone vs any ICS/LABA plus LAMA combination (errors in primary DPI)
ELLIPTA FF/VI (n=50) 5 (10) 45 (90) ‒ ‒
ELLIPTA FF/VI plus LAMA, and Turbuhaler BUD/FOR
plus LAMA, and DISKUS FP/SAL plus LAMA (n=150)
38 (25) 112 (75) 2.29 (0.85–6.16; 0.100) 2.64 (0.99–7.02; 0.051)
Turbuhaler BUD/FOR plus Handihaler TIO, and
DISKUS FP/SAL plus Handihaler TIO (n=99)
32 (32) 67 (68) 3.19 (1.13–9.00; 0.028) 3.96 (1.47–10.65; 0.006)
ELLIPTA FF/VI alone vs any ICS/LABA plus LAMA combination (errors in both DPIs considered)
ELLIPTA FF/VI (n=50) 5 (10) 45 (90) ‒ –
ELLIPTA FF/VI plus LAMA, and Turbuhaler BUD/FOR
plus LAMA, and DISKUS FP/SAL plus LAMA (n=150)
61 (41) 89 (59) 4.89 (1.85–12.90; 0.001) 5.48 (2.11–14.28; <0.001)
Turbuhaler BUD/FOR plus Handihaler TIO, and
DISKUS FP/SAL plus Handihaler TIO (n=99)
50 (51) 49 (49) 7.01 (2.51–19.54; <0.001) 8.43 (3.17–22.39; <0.001)
ELLIPTA FF/VI alone or plus LAMA vs other ICS/LABA DPIs alone or plus LAMA (errors in primary DPI)
ELLIPTA FF/VI, and ELLIPTA FF/VI plus LAMA (n=100) 11 (11) 89 (89) ‒ ‒
Turbuhaler BUD/FOR, and Turbuhaler BUD/FOR plus
LAMA (n=100)
39 (39) 61 (61) 3.99 (1.81–8.83; <0.001) 4.86 (2.34–10.08; <0.001)
DISKUS FP/SAL, and DISKUS FP/SAL plus LAMA
(n=100)
26 (26) 74 (74) 2.18 (0.94–5.06; 0.069) 2.71 (1.27–5.76; 0.010)
ELLIPTA FF/VI alone or plus LAMA vs other ICS/LABA DPIs alone or plus LAMA (errors in both DPIs considered)
ELLIPTA FF/VI, and ELLIPTA FF/VI plus LAMA (n=100) 16 (16) 84 (84) ‒ ‒
Turbuhaler BUD/FOR, and Turbuhaler BUD/FOR plus
LAMA (n=100)
47 (47) 53 (53) 3.94 (1.86–8.34; <0.001) 4.73 (2.39–9.36; <0.001)
DISKUS FP/SAL, and DISKUS FP/SAL plus LAMA
(n=100)
36 (36) 64 (64) 2.39 (1.09–5.26; 0.030) 2.96 (1.47–5.94; 0.002)
Notes: aPre-specified analyses were performed with the covariate of time on primary DPI included in the logistic regression model; bPost-hoc sensitivity analyses excluded
the covariate of time on primary DPI from the model due to confounding with DPI type (ELLIPTA and Breezhaler users were more likely to have used their inhaler for
a shorter time than Turbuhaler, DISKUS and HandiHaler users); cRounded from 0.999.
Abbreviations: BUD, budesonide; CI, confidence interval; DPI, dry-powder inhaler; FF, fluticasone furoate; FOR, formoterol; FP, fluticasone propionate; GLY, glycopyrronium;
ICS, inhaled corticosteroid; IND, indacaterol; LABA, long acting β2-agonist; LAMA, long-acting muscarinic antagonist; OR, odds ratio; SAL, salmeterol; TIO, tiotropium; UMEC,
umeclidinium; VI, vilanterol; V1, Visit 1.
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Percentage of Patients Making ≥1 Critical
Error at V1: ELLIPTA FF/VI Alone versus
ICS/LABA DPIs Plus LAMA
The comparison of ELLIPTA FF/VI alone versus ICS/LABA
DPIs plus LAMADPIs effectively simulates the comparison
of ELLIPTA SITT versus MITT (although in this investiga-
tion, ELLIPTAwas not used by any patients to deliver a triple
therapy regimen). When considering only errors with the
primary ICS/LABA DPI, the number of patients making ≥1
critical error was 5/50 (10%) with ELLIPTA FF/VI and 6/50
(12%) with ELLIPTA FF/VI plus LAMA (Table 3).
Compared with ELLIPTA FF/VI alone, the OR for patients
making ≥1 critical error was 1.22 (95% CI 0.36–4.15;
P=0.746) with ELLIPTA FF/VI plus LAMA, but when con-
sidering errors in either the primary or LAMA DPI, the
number of patients making ≥1 critical error increased to 11/
50 (22%) with ELLIPTA FF/VI plus LAMA, corresponding
to an OR of 2.50 (95% CI 0.82–7.66; P=0.108) (Table 3).
When considering errors with the primary DPI for patients
using any ICS/LABA plus LAMA combination (ie, ELLIPTA
FF/VI, Turbuhaler BUD/FOR, or DISKUS FP/SAL, respec-
tively, plus Handihaler TIO or ELLIPTA UMEC, respec-
tively), ≥1 critical error was made by 38/150 (25%) patients.
This corresponded to an OR of 2.29 (95% CI 0.85–6.16;
P=0.100) versus ELLIPTA FF/VI alone. Including errors in
either the primary or LAMA DPI, the number of patients
making ≥1 critical error increased to 61/150 (41%). This
corresponded to an OR of 4.89 (95% CI 1.85–12.90;
P=0.001) versus ELLIPTA FF/VI alone.
A further post-hoc analysis comparing ELLIPTA FF/VI
alone (n=50) with ICS/LABA plus LAMA combinations not
using ELLIPTA (ie, Turbuhaler BUD/FOR and DISKUS FP/
SAL each plus Handihaler TIO; n=99) found that signifi-
cantly more patients using ICS/LABA plus LAMAmade ≥1
critical error with the primary ICS/LABADPI (10% vs 32%,
OR 3.19, 95% CI 1.13–9.00; P=0.028) or with either DPI
(10% vs 51%, OR 7.01, 95% CI 2.51–19.54; P<0.001).
Percentage of Patients Making ≥1 Critical
Error at V1: ELLIPTA FF/VI Alone or Plus
LAMA versus Other ICS/LABA DPIs
Alone or Plus LAMA
For patients prescribed an ICS/LABA DPI, considering
both those using it alone and those using it together with
a LAMA, the number making ≥1 critical error with the
primary ICS/LABA DPI was 11/100 (11%) with ELLIPTA
FF/VI, 39/100 (39%) with Turbuhaler BUD/FOR, and 26/
100 (26%) with DISKUS FP/SAL (Table 3). Compared
with ELLIPTA FF/VI, the OR for patients making ≥1
critical error with the primary DPI was 3.99 (95% CI
1.81–8.83; P<0.001) with Turbuhaler BUD/FOR, and
2.18 (95% CI 0.94–5.06; P=0.069) with DISKUS FP/
SAL (Table 3). When these comparisons considered criti-
cal errors made with either the primary or LAMA DPI, the
number of patients making ≥1 critical error increased and
was 16/100 (16%) for ELLIPTA FF/VI plus LAMA, 47/
100 (47%) for Turbuhaler BUD/FOR plus LAMA, and 36/
100 (36%) for DISKUS FP/SAL plus LAMA. Compared
with ELLIPTA FF/VI plus LAMA, the OR for patients
making ≥1 critical error with the primary ICS/LABA DPI
and/or LAMA DPI was 3.94 (95% CI 1.86–8.34; P<0.001)
with Turbuhaler BUD/FOR plus LAMA, and 2.39 (95%
CI 1.09–5.26; P=0.030) with DISKUS FP/SAL plus
LAMA (Table 3).
Percentage of Patients Making ≥1 Critical
Error with their Prescribed DPI at V2
At V2, the percentage of patients making ≥1 critical error
was reduced compared to V1 across all single DPIs and
combinations tested (Figure 2; Table 4).
It was again notable that the ELLIPTA DPI, as either
a single ICS/LABA DPI or single LAMA/LABA DPI, had
the lowest critical error rate. The number of patients mak-
ing ≥1 critical error with ELLIPTA FF/VI at V2 was 0/50
(0%), compared with 4/48 (8%) with Turbuhaler BUD/
FOR (OR 7.35, 95% CI 0.41–132.14; P=0.176) and 5/45
(11%) with DISKUS FP/SAL (OR 9.30, 95% CI 0.53–-
164.47; P=0.128).
For LAMA or LAMA/LABA single-inhaler compari-
sons, 0% of patients (0/50) made ≥1 critical error with
ELLIPTA UMEC/VI or UMEC, compared with 10/47
(21%) with HandiHaler TIO (OR 20.45, 95% CI 1.19–-
351.61; P=0.038) and 8/47 (17%) with Breezhaler IND/
GLY or GLY (OR 18.78, 95% CI 1.13–311.67; P=0.041)
(Figure 2; Table 4).
Percentage of Patients Making ≥1 Overall
Error with their Prescribed DPI
The correct-use checklists recorded all errors, referred to
as overall errors (critical errors and non-critical errors).
This enabled additional planned analyses of overall errors
to be conducted. Comparisons were analogous to those
reported above for critical errors.
Collier et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:151308
Consistent with the data for critical errors, overall errors
were made least often with the ELLIPTA DPI, as either
a single ICS/LABA DPI or single LAMA/LABA DPI. The
number of patients making ≥1 overall error with ELLIPTA
FF/VI at V1 was 17/50 (34%), compared with 32/50 (64%)
with Turbuhaler BUD/FOR (OR 2.40, 95% CI 1.02–5.68;
P=0.045) and 30/50 (60%) with DISKUS FP/SAL (OR 1.82,
95% CI 0.77–4.32; P=0.172) (Table S6). For LAMA or
LAMA/LABA single-inhaler comparisons, 19/51 (37%)
patients made ≥1 overall error with ELLIPTA UMEC/VI or
UMEC, compared with 37/50 (74%) with HandiHaler TIO
(OR 2.99, 95% CI 1.23–7.27; P=0.016) and 27/49 (55%)
with Breezhaler IND/GLYor GLY (OR 1.75, 95% CI 0.77–-
3.94; P=0.179) (Table S6).
In comparisons of ELLIPTA FF/VI alone versus ICS/
LABA DPIs plus LAMA, addition of a LAMA DPI to
ELLIPTA FF/VI had no effect on the number of patients
making ≥1 overall error with the primary DPI (17/50, 34%);
however, the number increased when errors with either DPI
were considered (23/50, 46%; OR 1.93, 95% CI 0.84–4.43;
P=0.120). Similarly, more patients made ≥1 overall error
with any ICS/LABA plus LAMA compared with ELLIPTA
FF/VI alone, and with any ICS/LABA alone or plus a LAMA
compared with ELLIPTA FF/VI alone or plus a LAMA; this
was true when considering errors with the primary DPI, or
errors with either DPI (Table S6).
Similar patterns were observed at V2 (Table S7), where
again the overall error rate was reduced compared to V1
across all single DPIs and combinations tested. The
ELLIPTA DPI demonstrated the lowest overall error rate
(FF/VI: 6/50, 12%; UMEC or UMEC/VI: 4/50, 8%) com-
pared with equivalent ICS/LABA DPIs (Turbuhaler BUD/
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Figure 2 Percentage of patients making ≥1 critical error with the primary DPI at V2, 6 weeks after training. LAMA represents ELLIPTA UMEC or HandiHaler TIO.
Abbreviations: BUD, budesonide; DPI, dry-powder inhaler; FF, fluticasone furoate; FOR, formoterol; FP, fluticasone propionate; GLY, glycopyrronium; IND, indacaterol;
LAMA, long-acting muscarinic antagonist; SAL, salmeterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol; V2, Visit 2.
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Table 4 Percentage of Patients Making ≥1 Critical Error with their Prescribed DPI(s) at V2
DPI Group Patients Making
≥1 Critical Error,
n (%)
Patients Making
No Critical Errors,
n (%)
OR vs ELLIPTA (95% CI; P-value)
Pre-Specified
Analysesa
Post-Hoc Sensitivity
Analysesb
ICS/LABA
ELLIPTA FF/VI (n=50) 0 50 (100) ‒ ‒
Turbuhaler BUD/FOR (n=48) 4 (8) 44 (92) 7.35 (0.41–132.14; 0.176) 10.21 (0.52–200.90; 0.126)
DISKUS FP/SAL (n=45) 5 (11) 40 (89) 9.30 (0.53–164.47; 0.128) 13.72 (0.72–263.13; 0.082)
LAMA/LABA or LAMA only
ELLIPTA UMEC or UMEC/VI (n=50) 0 50 (100) ‒ ‒
HandiHaler TIO (n=47) 10 (21) 37 (79) 20.45 (1.19–351.61; 0.038) 28.28 (1.56–512.53; 0.024)
Breezhaler IND/GLY or GLY (n=47) 8 (17) 39 (83) 18.78 (1.13–311.67; 0.041) 21.74 (1.18–399.54; 0.038)
ELLIPTA FF/VI alone vs ELLIPTA FF/VI plus LAMA (errors in primary DPI)
ELLIPTA FF/VI (n=50) 0 50 (100) ‒ ‒
ELLIPTA FF/VI plus LAMA (n=49) 3 (6) 46 (94) 8.87 (0.48–162.78; 0.141) 7.60 (0.37–155.76; 0.188)
ELLIPTA FF/VI alone vs ELLIPTA FF/VI plus LAMA (errors in both DPIs considered)
ELLIPTA FF/VI (n=50) 0 50 (100) ‒ ‒
ELLIPTA FF/VI plus LAMA (n=49) 4 (8) 45 (92) 12.15 (0.68–216.82; 0.090) 9.99 (0.51–196.44; 0.130)
ELLIPTA FF/VI alone vs any ICS/LABA plus LAMA combination (errors in primary DPI)
ELLIPTA FF/VI (n=50) 0 50 (100) ‒ ‒
ELLIPTA FF/VI plus LAMA, and Turbuhaler BUD/FOR
plus LAMA, and DISKUS FP/SAL plus LAMA (n=144)
12 (8) 132 (92) 7.78 (0.49–124.12; 0.147) 9.79 (0.55–173.30; 0.120)
Turbuhaler BUD/FOR plus Handihaler TIO, and
DISKUS FP/SAL plus Handihaler TIO (n=94)
8 (9) 86 (91) 6.16 (0.37–103.65; 0.207) 10.21 (0.56–185.88; 0.117)
ELLIPTA FF/VI alone vs any ICS/LABA plus LAMA combination (errors both DPIs considered)
ELLIPTA FF/VI (n=50) 0 50 (100) ‒ ‒
ELLIPTA FF/VI plus LAMA, and Turbuhaler BUD/FOR
plus LAMA, and DISKUS FP/SAL plus LAMA (n=144)
18 (13) 126 (88) 11.91 (0.75–188.21; 0.079) 15.06 (0.87–262.04; 0.063)
Turbuhaler BUD/FOR plus Handihaler TIO, and
DISKUS FP/SAL plus Handihaler TIO (n=94)
13 (14) 81 (86) 10.21 (0.62–167.57; 0.104) 17.21 (0.97–304.03; 0.052)
ELLIPTA FF/VI alone or plus LAMA vs other ICS/LABA DPIs alone or plus LAMA (errors in primary DPI)
ELLIPTA FF/VI, and ELLIPTA FF/VI plus LAMA
(n=99)
3 (3) 96 (97) ‒ ‒
Turbuhaler BUD/FOR, and Turbuhaler BUD/FOR
plus LAMA (n=97)
7 (7) 90 (93) 2.09 (0.38–11.39; 0.395) 3.20 (0.60–17.14; 0.175)
DISKUS FP/SAL, and DISKUS FP/SAL plus LAMA
(n=91)
11 (12) 80 (88) 3.25 (0.61–17.24; 0.166) 5.41 (1.06–27.61; 0.042)
ELLIPTA FF/VI alone or plus LAMA vs other ICS/LABA DPIs alone or plus LAMA (errors in both DPIs considered)
ELLIPTA FF/VI and ELLIPTA FF/VI plus LAMA (n=99) 4 (4) 95 (96) ‒ ‒
Turbuhaler BUD/FOR and Turbuhaler BUD/FOR
plus LAMA (n=97)
11 (11) 86 (89) 2.67 (0.52–13.69; 0.239) 4.27 (0.85–21.49; 0.078)
DISKUS FP/SAL and DISKUS FP/SAL plus LAMA
(n=91)
12 (13) 79 (87) 2.93 (0.57–15.13; 0.200) 5.13 (1.03–25.55; 0.046)
Notes: aPre-specified analyses were performed with the covariate of time on primary DPI included in the logistic regression model; bPost-hoc sensitivity analyses excluded
the covariate of time on primary DPI from the model due to confounding with DPI type (ELLIPTA and Breezhaler users were more likely to have used their inhaler for
a shorter time than Turbuhaler, DISKUS and HandiHaler users).
Abbreviations: BUD, budesonide; CI, confidence interval; DPI, dry-powder inhaler; FF, fluticasone furoate; FOR, formoterol; FP, fluticasone propionate; GLY, glycopyrronium;
ICS, inhaled corticosteroid; IND, indacaterol; LABA, long acting β2-agonist; LAMA, long-acting muscarinic antagonist; OR, odds ratio; SAL, salmeterol; TIO, tiotropium; UMEC,
umeclidinium; VI, vilanterol; V2, Visit 2.
Collier et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:151310
FOR: 17/48, 35%, OR 3.48, 95% CI 1.22–9.96; P=0.020;
DISKUS FP/SAL: 12/45, 27%, OR 2.28, 95% CI 0.76–6.90;
P=0.143) and LAMA or LAMA/LABA DPIs (HandiHaler
TIO: 17/47, 36%, OR 5.27, 95% CI 1.62–17.19; P=0.006;
Breezhaler IND/GLYor GLY: 15/47, 32%, OR 4.66, 95% CI
1.48–14.67; P=0.009).
Discussion
Errors in inhaler technique remain an ever-present issue in
COPD maintenance therapy, and the association between
these errors, particularly critical errors, and reduced treat-
ment efficacy is widely acknowledged.3 As such, the opti-
mization of inhaler technique through training represents
an important route by which the efficacy of maintenance
therapy may be improved.15
This study was designed to assess the ability of patients
with COPD to correctly use their prescribed DPI in a low-
intervention setting. Here, the notion that inhaler training
reduces the percentage of patients making critical (and
overall) errors is clearly demonstrated by the comparison
of results between V1 and V2, despite an interval of 6
weeks. Our findings also reveal differences in ease of use
for each inhaler, exemplified by large differences in criti-
cal and overall error rates in the absence of training.
For the single DPIs (ICS/LABA, and LAMA or
LAMA/LABA), the ELLIPTA DPI was associated with
the lowest percentage of patients making ≥1 critical error
at V1, providing agreement with previous, similar
studies.6,14 This difference was statistically significant for
all but one of the single-DPI comparisons at V1; only the
comparison between ELLIPTA FF/VI and DISKUS FP/
SAL did not reach statistical significance (P=0.114).
Findings from the pre-specified analyses were confirmed
in the additional post-hoc sensitivity analyses, in which the
covariate of time on primary DPI was excluded due to
confounding with type of DPI used.
Recent findings from a randomized, open-label, pla-
cebo-inhaler crossover study, including ELLIPTA, indi-
cated that patients with COPD make fewer critical errors
with single-inhaler regimens compared with multiple-
inhaler regimens.5 This idea of improved technique when
using fewer inhalers is also supported here by comparing
ELLIPTA FF/VI with ICS/LABA DPIs plus LAMA,
which demonstrated relatively high ORs for ≥1 critical
error in favor of ELLIPTA at both V1 and V2. The
smaller, non-significant differences in critical errors
observed between ELLIPTA FF/VI and ELLIPTA FF/VI
plus LAMA likely reflect the proportion of patients (23/
50) already using an ELLIPTA DPI for the secondary
LAMA.
The comparison of ELLIPTA FF/VI versus the ICS/
LABA plus LAMA combination group is essentially equiva-
lent to simulating SITTwith ELLIPTAversusMITTwith any
DPIs. In additional post-hoc analyses, patients using
ELLIPTA ICS/LABA (simulated SITT) demonstrated sig-
nificantly fewer critical errors at V1 compared with an ICS/
LABA plus LAMA comparator group that excluded the
ELLIPTADPIs (ie, non-ELLIPTAMITT); a similar but non-
significant trend was observed at V2.
Incorrect inhaler technique is common and has been
well documented in the literature.2,7,16 A systematic litera-
ture review of studies evaluating incorrect use of DPIs by
patients with asthma or COPD found that 4–94% of
patients (depending on the type of DPI and method of
assessment) did not use their inhalers correctly, while up
to 25% had never received verbal instruction on inhaler
technique.16 Physical demonstration and verbal instruction
have been shown to markedly reduce critical errors with
DPIs, including ELLIPTA and Breezhaler.17 Our findings
also clearly show that verbal instruction substantially
reduces the number of critical and overall inhaler errors
with these, and other, DPIs. Considering five different
DPIs, we found that ≥1 critical error occurred in 10–40%
of patients at V1, least often with the ELLIPTA DPI and
most often with the Turbuhaler DPI. Error rates were
reduced after training for all five DPIs at V2 (0–21%);
this is comparable with previous studies and meta-analyses
demonstrating a reduction in errors after visual demonstra-
tion or additional training.6,17,18 In this study, exhaling into
the inhaler mouthpiece prior to inhalation was the most
common critical error with the ELLIPTA FF/VI, DISKUS
FP/SAL and Breezhaler IND/GLYor GLY DPIs. This may
introduce moisture into the mouthpiece, causing clumping
of the medication.19
The enrollment of patients on their prescribed DPIs is
a notable strength of this study, adding an element of real-
world design to the protocol and meaning results more
accurately reflect error rates in the clinic. The incorpora-
tion of minimal study visits also mimics real-world sce-
narios, allowing patients to feel less constrained by the
schedule of clinical trial protocol visits.
However, the results of this study may not be widely
comparable with those of similar, existing studies because
patients were enrolled on their currently prescribed DPI.
Previous studies have tended to use inhaler-naïve patients
and, as such, the critical error rates reported in this study
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may be lower than generally expected based on existing
data. Moreover, this study was open-label and non-
randomized, though baseline and demographic character-
istics were broadly similar across all treatment groups and
much of this potential bias was thus reduced. Additionally,
participating sites did not recruit an equal number of
participants using each of the DPIs tested but all site
staff assessing participants for errors in correct use
received the same training on all DPIs, to limit the effect
of this.
A further limitation of this study is that conclusions
regarding the relationship between inhaler errors and treat-
ment outcomes cannot be drawn, as clinical outcomes
were not assessed. Previous studies and reviews have,
however, highlighted a positive correlation between inha-
ler technique and treatment outcomes7,15 and critical errors
may have an adverse impact on patient outcomes.20
In this study, the retention of inhaler training knowledge
was assessed over 6 weeks. Longer-term studies are needed
to further understand the retention of inhaler training over
time periods when patients would not typically receive
further guidance in clinical settings. Future studies in this
area may also make use of additional inhalers not considered
here to provide a more comprehensive overview of inhalers
available in clinical practice, and should also consider patient
compliance and satisfaction, to better understand how these
factors may impact clinical outcomes.21
The observed differences between visits in this low-
intervention study clearly show the value and importance
of verbal instruction on correct inhaler use by HCPs. In
a recent review of 39 studies of inhalation technique
education for both asthma and COPD, 89% involved
a physical or video demonstration of inhaler technique,
and 90% of the same studies reported a significant
improvement in inhaler technique, indicating a strong rela-
tionship between training and improved technique.15
Physical or video demonstration of correct inhaler techni-
que may be ideal in most cases, the latter being an
approach that might easily be adopted by most practices
(eg, during patient waiting times).
Conclusion
Patients with COPD can make critical inhaler errors fre-
quently, though rates differ according to inhaler type.
Critical error rates were lower after verbal refresher training,
demonstrating the importance of HCP instruction on inhaler
technique for commonly used DPIs. In this study, the
ELLIPTA DPI resulted in fewer critical errors compared
with other ICS/LABA, and LAMA or LAMA/LABA DPIs
assessed in a low-intervention clinical setting in patients with
COPD. Our findings will help HCPs and patients make
informed decisions regarding the choice of, training with
and use of DPIs as an integral part of COPD maintenance
therapy regimens.
Abbreviations
BMI, body mass index; BUD, budesonide; CAT, COPD
Assessment Test; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; DPI, dry-powder inhaler;
FF, fluticasone furoate; FOR, formoterol; FP, fluticasone
propionate; GLY, glycopyrronium; HCP, healthcare profes-
sional; ICS, inhaled corticosteroid; IND, indacaterol; ITT,
intent-to-treat; LABA, long acting β2-agonist; LAMA,
long-acting muscarinic antagonist; MITT, multiple-
inhaler triple therapy; OR, odds ratio; SAL, salmeterol;
SD, standard deviation; SITT, single-inhaler triple therapy;
TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol;
V0, Visit 0; V1, Visit 1; V2, Visit 2.
Data Sharing Statement
Anonymized individual patient data and study documents
can be requested for further research from www.clinical
studydatarequest.com.
Acknowledgments
Trademarks are owned by or licensed to their respective
owners (the GlaxoSmithKline group of companies, and
AstraZeneca, Boehringer Ingelheim, and Novartis).
Editorial support (in the form of writing assistance, collating
author comments, assembling tables and figures, grammati-
cal editing, fact checking, and referencing) was provided by
Matthew HallamMSc(Res), andMolly Macpherson, BSc, of
Gardiner-Caldwell Communications (Macclesfield, UK) and
was funded by GlaxoSmithKline plc.
Author Contributions
All authors contributed to data analysis, drafting or revis-
ing the article, gave final approval of the version to be
published, and agree to be accountable for all aspects of
the work.
Funding
This study was funded by GlaxoSmithKline plc.
(ClinicalTrials.gov number NCT02982187; GlaxoSmithKline
plc. study 204981).
Collier et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:151312
Disclosure
David J Collier was supported in part by the NIHR Barts
Biomedical Research Centre. Job van der Palen reports per-
sonal fees from AstraZeneca, Boehringer Ingelheim, and
GlaxoSmithKline plc., and grants from Chiesi, outside the
submitted work. Logan Heyes was an employee of
GlaxoSmithKline plc. at the time of the study, and is cur-
rently employed by Pharmaceutical Management Agency
(PHARMAC). Dawn Midwinter, Kathryn Collison, Andy
Preece, Neil Barnes, and Raj Sharma are employees of, and
have shares in, GlaxoSmithKline plc. The authors report no
other conflicts of interest in this work.
References
1. GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease. 2019. Report, 2019. Last
accessed January 2019.
2. Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma
and COPD: systematic literature review and meta-analysis. NPJ Prim
Care Respir Med. 2017;27(1):22. doi:10.1038/s41533-017-0016-z
3. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma
and COPD: a systematic review of impact on health outcomes. Respir
Res. 2018;19(1):10. doi:10.1186/s12931-017-0710-y
4. Usmani OS. Choosing the right inhaler for your asthma or COPD
patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/
TCRM.S160365
5. van der Palen J, Moeskops-van Beurden W, Dawson CM, et al.
A randomized, open-label, single-visit, crossover study simulating
triple-drug delivery with Ellipta compared with dual inhaler combina-
tions in patients with COPD. Int J Chron Obstruct Pulmon Dis.
2018;13:2515–2523. doi:10.2147/COPD.S169060
6. van der Palen J, Thomas M, Chrystyn H, et al. A randomised
open-label cross-over study of inhaler errors, preference and time to
achieve correct inhaler use in patients with COPD or asthma: compar-
ison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir
Med. 2016;26:16079. doi:10.1038/npjpcrm.2016.79
7. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pul-
monary disease exacerbation and inhaler device handling: real-life
assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794.
doi:10.1183/13993003.01794-2016
8. Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in
asthma: common errors, barriers to use and recommended solutions.
Respir Med. 2013;107(1):37–46. doi:10.1016/j.rmed.2012.09.017
9. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains
common in real life and is associated with reduced disease control.
Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.005
10. Plaza V, Giner J, Rodrigo GJ, et al. Errors in the use of inhalers by
health care professionals: a systematic review. J Allergy Clin
Immunol Pract. 2018;6(3):987–995. doi:10.1016/j.jaip.2017.12.032
11. Self TH, Arnold LB, Czosnowski LM, et al. Inadequate skill of
healthcare professionals in using asthma inhalation devices.
J Asthma. 2007;44(8):593–598. doi:10.1080/02770900701554334
12. Ovchinikova L, Smith L, Bosnic-Anticevich S. Inhaler technique
maintenance: gaining an understanding from the patient’s perspec-
tive. J Asthma. 2011;48(6):616–624. doi:10.3109/02770903.2011.
580032
13. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of
inhaler devices in real life: an observational study in 3811 patients in
primary care. J Aerosol Med. 2003;16(3):249–254. doi:10.1089/
089426803769017613
14. van der Palen J, Thomas M, Chrystyn H, et al. Inhaler errors after
reading the patient information leaflet in patients with COPD:
a comparison of Ellipta® with five inhaler devices. Am J Respir
Crit Care Med. 2016;193:A6811.
15. Klijn SL, Hiligsmann M, Evers SMAA, et al. Effectiveness and
success factors of educational inhaler technique interventions in
asthma & COPD patients: a systematic review. NPJ Prim Care
Respir Med. 2017;27(1):24. doi:10.1038/s41533-017-0022-1
16. Lavorini F, Magnan A, Christophe Dubus J, et al. Effect of incorrect
use of dry powder inhalers on management of patients with asthma
and COPD. Respir Med. 2008;102(4):593–604. doi:10.1016/j.
rmed.2007.11.003
17. Man KN, Tian Z, Lam DC-L, et al. Satisfaction, preference and error
occurrence of three dry powder inhalers as assessed by a cohort naïve
to inhaler operation. Int J Chron Obstruct Pulmon Dis.
2018;13:1949–1963. doi:10.2147/COPD.S152285
18. Komase Y, Asako A, Kobayashi A, et al. Ease-of-use preference for
the ELLIPTA® dry powder inhaler over a commonly used single-
dose capsule dry powder inhaler by inhalation device-naïve Japanese
volunteers aged 40 years or older. Int J Chron Obstruct Pulmon Dis.
2014;9:1365–1375. doi:10.2147/COPD.S72762
19. Sulaiman I, Seheult J, Sadasivuni N, et al. The impact of common
inhaler errors on drug delivery: investigating critical errors with a dry
powder inhaler. J Aerosol Med Pulm Drug Deliv. 2017;30
(4):247–255. doi:10.1089/jamp.2016.1334
20. Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in
the CRITIKAL study: type, frequency, and association with asthma
outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–1081.e9.
doi:10.1016/j.jaip.2017.01.004
21. Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and
critical errors with Genuair and Breezhaler inhalers in patients with
COPD: a randomised, cross-over, multicentre study. NPJ Prim Care
Respir Med. 2015;25(1):15018. doi:10.1038/npjpcrm.2015.18
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
Publish your work in this journal
The International Journal of COPD is an international, peer-reviewed
journal of therapeutics and pharmacology focusing on concise rapid
reporting of clinical studies and reviews in COPD. Special focus is
given to the pathophysiological processes underlying the disease, inter-
vention programs, patient focused education, and self management
protocols. This journal is indexed on PubMed Central, MedLine
and CAS. The manuscript management system is completely online
and includes a very quick and fair peer-review system, which is
all easy to use. Visit http://www.dovepress.com/testimonials.php to
read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
Dovepress Collier et al
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 submit your manuscript | www.dovepress.com
DovePress
1313
